The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile
Open accessAbstract
Monofunctional platinum(II) complexes of general formula cis -[Pt(NH 3 ) 2 ( N -heterocycle)Cl]Cl bind DNA at a single site, inducing little distortion in the double helix. Despite this behavior, these compounds display significant antitumor properties, with a different spectrum of activity than that of classic bifunctional cross-linking agents like cisplatin. To discover the most potent monofunctional platinum(II) compounds, the N -heterocycle was systematically varied to generate a small library of new compounds, with guidance from the X-ray structure of RNA polymerase II (Pol II) stalled at a monofunctional pyriplatin-DNA adduct. In pyriplatin, the N -heterocycle is pyridine. The most effective complex evaluated was phenanthriplatin, cis -[Pt(NH 3 ) 2 (phenanthridine)Cl]NO 3 , which exhibits significantly greater activity than the Food and Drug Administration-approved drugs cisplatin and oxaliplatin. Studies of phenanthriplatin in the National Cancer Institute 60-cell tumor panel screen revealed a spectrum of activity distinct from that of these clinically validated anticancer agents. The cellular uptake of phenanthriplatin is substantially greater than that of cisplatin and pyriplatin because of the hydrophobicity of the phenanthridine ligand. Phenanthriplatin binds more effectively to 5′-deoxyguanosine monophosphate than to N -acetyl methionine, whereas pyriplatin reacts equally well with both reagents. This chemistry supports DNA as a viable cellular target for phenanthriplatin and suggests that it may avoid cytoplasmic platinum scavengers with sulfur-donor ligands that convey drug resistance. With the use of globally platinated Gaussia luciferase vectors, we determined that phenanthriplatin inhibits transcription in live mammalian cells as effectively as cisplatin, despite its inability to form DNA cross-links.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sheldrick, G. M. (2008) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767307043930 · Cited by 87,804
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Self-citationStructure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Self-citationThe NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Self-citationCisplatin and platinum drugs at the molecular level (Review)
Boulikas, T., & Vougiouka, M. (2003) · Oncology Reports · doi:10.3892/or.10.6.1663 · Cited by 729
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Self-citationMitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Dhar, S., & Lippard, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912276106 · Cited by 369
Self-citationPractical suggestions for better crystal structures
Müller, P. (2009) · Crystallography Reviews · doi:10.1080/08893110802547240 · Cited by 285
Lovejoy, K. S., Todd, R. C., Zhang, S., McCormick, M. S., D'Aquino, J. A., Reardon, J. T., Sancar, A., Giacomini, K. M., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803441105 · Cited by 238
Self-citationPinto, A. L., & Lippard, S. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.14.4616 · Cited by 219
Self-citationWang, D., Zhu, G., Huang, X., & Lippard, S. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002565107 · Cited by 133
Self-citationMello, J. A., Lippard, S. J., & Essigmann, J. M. (1995) · Biochemistry · doi:10.1021/bi00045a020 · Cited by 101
Self-citationTranscription Inhibition by Platinum−DNA Cross-Links in Live Mammalian Cells
Ang, W. H., Myint, M., & Lippard, S. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja101495v · Cited by 97
Self-citationZhu, G., Myint, M., Ang, W. H., Song, L., & Lippard, S. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-3151 · Cited by 75
Self-citationHuxley, M., Sánchez-Cano, C., Browning, M. J., Navarro‐Ranninger, C., Quiroga, A. G., Rodger, A., & Hannon, M. J. (2010) · Dalton Transactions · doi:10.1039/c0dt00838a · Cited by 66
Bursová, V., Kašpárková, J., Hofr, C., & Brabec, V. (2004) · Biophysical Journal · doi:10.1529/biophysj.104.051771 · Cited by 29
Cited by
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Self-citationCisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2014) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 630
Self-citationBruno, P. M., Liu, Y., Park, G. Y., Murai, J., Koch, C. E., Eisen, T. J., Pritchard, J. R., Pommier, Y., Lippard, S. J., & Hemann, M. T. (2017) · Nature Medicine · doi:10.1038/nm.4291 · Cited by 519
Self-citation
Metadata
- Authors
- Park, G. Y., Wilson, J. J., Song, Y., & Lippard, S. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-07-06
- Volume
- 109
- Issue
- 30
- Pages
- 11987-11992
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2033271093
- Cited by
- 330
- References
- 18
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.